Neoadjuvant radiotherapy for retroperitoneal sarcoma: A systematic review

Cheng, Hao; Miura, John T.; Lalehzari, Mona; Rajeev, Rahul; Donahue, Amy; Bedi, Meena; Gamblin, T. Clark; Turaga, Kiran K.; Johnston, Fabian M.

doi:10.1002/jso.24221

Cited by 28 publications

(28 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…4 In general, preoperative and postoperative radiation therapy reduce the risk of local recurrence in DL, but does not appear to have significant benefit in overall survival. [30][31][32] The role of adjunctive chemotherapy remains controversial. 29,30,33,34 The recurrent oncogenic role of MDM2 and CDK4 in both WDL and DL prompted significant effort to develop targeted therapies.…”

Section: Clinical Featuresmentioning

confidence: 99%

Dedifferentiated Liposarcoma With Myofibroblastic Differentiation

Wang¹,

Lucas

2018

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.— Liposarcoma is divided into myxoid, pleomorphic, well-differentiated, and dedifferentiated subtypes. Dedifferentiated liposarcoma displays the greatest histomorphologic diversity, including a subset with myofibroblastic differentiation that shares similarities with a spectrum of reactive, benign, and malignant soft tissue lesions. Misdiagnosis may lead to deleterious consequences, as dedifferentiated liposarcoma differs significantly in its prognosis and treatment from its mimics. Objective.— To review the clinicopathologic, immunohistochemical, and molecular features of the myofibroblastic variant of dedifferentiated liposarcoma as well as the key distinguishing features from its mimics. Data Sources.— Review of pertinent literature on major features and current understanding of dedifferentiated liposarcoma with myofibroblastic differentiation. Conclusions.— The myofibroblastic variant of dedifferentiated liposarcoma is an uncommon and underrecognized sarcoma with several important differential diagnoses, and likely represents the major subset of aggressive retroperitoneal tumors that may have been misdiagnosed as desmoid-type fibromatosis, inflammatory myofibroblastic tumor, or another type of sarcoma in the past.

show abstract

Section: Clinical Featuresmentioning

confidence: 99%

Dedifferentiated Liposarcoma With Myofibroblastic Differentiation

Wang¹,

Lucas

2018

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

show abstract

“…At a 6-month follow-up of the present case, no signs of metastasis or recurrence were observed. Previously, more and more investigations and case reports are inclined to preserve-organ surgery combined with neoadjuvant chemotherapy and radiotherapy to improve the clinical outcome (12)(13)(14). It is of great surprise that a new drug, Eribulin mesylate (Halaven), has been approved to treat non-resectable or metastasized liposarcoma (15).…”

Section: Discussionmentioning

confidence: 99%

“…However, if free margins cannot be achieved by combined organ resection, the decision should be made as to whether combined organ resection can be performed, particularly in low-grade tumor types. Maybe R1 or R2 resection combined with neoadjuvant chemotherapy and radiotherapy are a novel therapeutic method (5,13). Therefore, each aspect of the tumor histological characteristics, the quality of life of the patients, the complications of organ-resection, the benefit of the R0 resection and the long-team survival rate must be considered.…”

Section: Discussionmentioning

confidence: 99%

Huge retroperitoneal liposarcoma with renal involvement requires nephrectomy: A case report and literature review

Yang¹,

Zhao²,

Chun³

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract.A 60-year-old female visited Guihang Guiyang Hospital (Guiyang, China). She presented with abdominal pain in the right side for the previous 2-months, with a touchable mass identified for the previous 1-month. Computed tomography with magnetic resonance imaging revealed a huge mass in the right abdomen. The diagnosis of well-differentiated retroperitoneal liposarcoma with renal involvement was made. During surgery, the tumor was removed, including the fatty renal capsule; however, the kidney was preserved. It is currently debatable whether resection of adjacent organs is required to obtain the negative margins. Conventional viewpoints advise that multi-organ resection is required in order to obtain the negative-margin. However, even if an R0 resection is achieved, the local recurrence rate remains markedly high. Additionally, the complications of organ resection have more impact on patients. Radiotherapy and chemotherapy are an important adjuvant method for these patients. In conclusion, retroperitoneal liposarcoma is a rare disease with a high rate of recurrence. Complete resection is the predominant treatment; however, combined resection of adjacent organs must be considered.

show abstract

“…According to the evaluated treatment, 13 SRs appraised chemotherapy therapies [15, 18, 21, 25-27, 30-32, 37-39]; 5 SRs evaluated radiotherapy interventions [19,22,23,33,36]; 2 SRs assessed surgical interventions [24,34]; 1 SR assessed a combination of surgery (cytoreduction) plus intraperitoneal chemotherapy [28]; and finally 3 SRs assessed a therapy at the forefront named isolated limb perfusion (ILP) [20,29,35].…”

Section: Characteristics and Quality Of Systematic Reviewsmentioning

confidence: 99%

“…6. Patients with retroperitoneal sarcoma: Two SRs [22,36] evaluated different combinations of radiotherapy. In total, two non-controlled trials and 33 observational studies were included.…”

Section: Patients With Endometrial Stromal Sarcoma Localisedmentioning

confidence: 99%

Evidence mapping based on systematic reviews of therapeutic interventions for soft tissue sarcomas

Ballesteros¹,

Montero

López‐Pousa

et al. 2019

Clin Transl Oncol

View full text Add to dashboard Cite

Purpose Soft tissue sarcomas are a heterogeneous group of rare tumours of mesenchymal origin. Evidence mapping is one of the most didactic and friendly approaches to organise and summarise the range of research activity in broad topic fields. The objective of this evidence mapping is to identify, describe and organise the current available evidence about therapeutic interventions on soft tissues sarcomas. Methods We followed the methodology of global evidence mapping. We performed a search of the PubMed, EMBASE, The Cochrane Library and Epistemonikos to identify systematic reviews (SRs) with or without meta-analyses published between 1990 and March 2016. Two independent literature reviewers assessed eligibility and extracted data. Methodological quality of the included systematic reviews was assessed using AMSTAR. We organised the results according to identified PICO questions and used tables and a bubble plot to display the results. Results The map is based on 24 SRs that met eligibility criteria and included 66 individual studies. Three-quarters were either observational or uncontrolled clinical trials. The quality of the included SRs was in general moderate or high. We identified 64 PICO questions from them. The corresponding results mostly favoured the intervention arm. Conclusions This evidence mapping was built on the basis of SRs, which mostly included non-experimental studies and were qualified by the AMSTAR tool as of moderate quality. The evidence mapping created from PICO questions is a useful approach to describe complex and huge clinical topics through graphical media and orientate further research to fulfil the existing gaps. However, it is important to delimitate the steps of the evidence mapping in a pre-established protocol.

show abstract

Neoadjuvant radiotherapy for retroperitoneal sarcoma: A systematic review

Cited by 28 publications

References 51 publications

Dedifferentiated Liposarcoma With Myofibroblastic Differentiation

Dedifferentiated Liposarcoma With Myofibroblastic Differentiation

Huge retroperitoneal liposarcoma with renal involvement requires nephrectomy: A case report and literature review

Evidence mapping based on systematic reviews of therapeutic interventions for soft tissue sarcomas

Contact Info

Product

Resources

About